Factors associated with neuropsychiatric side effects after STN-DBS in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Witt, Karsten ^a   Daniels, Christine ^b   Volkmann, Jens ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Behavior; Cognition; Deep brain stimulation; Dementia; Mood; Parkinson's disease

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; LONG ACTING DRUG; NORTRIPTYLINE;

APATHY; ARTICLE; BASAL GANGLION; BEHAVIOR; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; DEPRESSION; EMOTION; EUPHORIA; FACILITATION; HUMAN; HYPOMANIA; MENTAL DISEASE; MOVEMENT PERCEPTION; NERVE STIMULATION; NEUROMODULATION; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SUBTHALAMIC NUCLEUS; SUICIDE; THINKING; COGNITION; KNOWLEDGE; NEUROPSYCHIATRY; PEROPERATIVE CARE; POSTOPERATIVE CARE;

EID: 84858678542     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70052-9     Document Type: Article

References (14)

1. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
2. Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
3. Volkmann J, Daniels C, Witt K. Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010;6:487-98.
4. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Schupbach M, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008;131:2720-8.
5. Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008;7:605-14.
6. Okun MS, Fernandez HH, Wu SS, Kirsch-Darrow L, Bowers D, Bova F, et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol 2009;65:586-95.
7. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, et al. Nonmotor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-27.
8. Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2006;18:397-401.
9. Reiff J, Schmidt N, Riebe B, Breternitz R, Aldenhoff J, Deuschl G, et al. Subthreshold depression in Parkinson's disease. Mov Disord 2011;26:1740-3.
10. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a metaanalysis. Lancet Neurol 2006;5:578-88.
11. Daniels C, Krack P, Volkmann J, Pinsker MO, Krause M, Tronnier V, et al. Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2010;25:1583-9.
12. York MK, Wilde EA, Simpson R, Jankovic J. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci 2009;287:159-71.
13. Witt K, Pulkowski U, Herzog J, Lorenz D, Hamel W, Deuschl G, et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 2004;61:697-700.
14. Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007;318: 1309-12.